Halia Therapeutics

Founded in 1958, Edwards Lifesciences is one of the leading manufacturers of heart valves and acute hemodynamic monitoring systems in the world. It specializes in providing treatment and monitoring products in the areas of anesthesiology, cardiology, radiology, emergency medicine, infection control, and cardiothoracic and cardiovascular surgery. The company s products include vigileo monitors, catheters, transducers, needleless cannulas, multichannel cables, tissue valves, carotid shunts and blood-management protection systems. It offers design, engineering, research, development and marketing services. The company supplies products from various manufacturers, such as Carpentier-Edwards, Cosgrove-Edwards, Fogarty, PERIMOUNT and Swan-Ganz. With annual sales revenue of more than $1 billion, it maintains a presence in over 100 countries worldwide and has a staff of nearly 5,000 employees. Headquartered in Irvine, Calif., Edwards Lifesciences maintains one of its manufacturing facilities in Midvale, Utah.

Utah Stem Cells is a leader in regenerative medicine and medical healthcare wellness. Utah Stem Cells was founded in 2014 by Dr. William Cimikoski, who is one of the pioneers in regeneration medicine. Dr. Cimikoski specializes in stem cell joint regeneration, bioidentical hormone replacement therapy, sexual wellness, medical aesthetics and medical weight loss management.

OmniLytics, Incorporated is a biotech company that is focused on developing safe, natural solutions for infectious disease and pest control. OmniLytics is located in Salt Lake City, Utah with official presence in Honduras, Ecuador, and El Salvador. With emphasis on bacteriophage technology, OmniLytics is pioneering research and development of bacteriophage solutions for pathogen control in the,, and defense markets. OmniLytics' proprietary formulas and processes optimize the use of natural bacteriophage for commercial applications. Bacteriophage solutions are natural, environmentally friendly, safe and effective. OmniLytics is primarily a research and development entity and derives its revenue from the sale of its products directly into certain markets or licensing agreements with its business units ( subsidiaries ) and strategic partners. OmniLytics' historical background dates back to 1954 and includes expansive research, development, knowledge, and expertise using natural products to control dangerous pathogens in a variety of market segments ; although the majority of the work over the last ten years has focused on agricultural diseases. As a result of this work, the company has developed several economical and effective products to control destructive plant and animal bacterial diseases that have become resistant to traditional antimicrobial agents. OmniLytics' products are made using bacteriophage mixtures. Bacteriophage, or phage , are viruses that attack only bacteria. Phage are very specific and only kill a particular species of bacteria. Unlike antibiotics and other chemicals, they will not kill other good bacteria, beneficial micro flora or fauna, and have no negative impact on other forms of life or the environment. As a result, the company's products provide a clean alternative to synthetically produced chemicals that leave behind toxic residues that can adversely affect human health and the environment.